Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 501-520

  Weston, Chris J ^a   Shepherd, Emma L ^a   Claridge, Lee C ^a,b   Rantakari, Pia ^c   Curbishley, Stuart M ^a   Tomlinson, Jeremy W ^d   Hubscher, Stefan G ^a,e   Reynolds, Gary M ^a   Aalto, Kristiina ^c   Anstee, Quentin M ^f   Jalkanen, Sirpa ^c   Salmi, Marko ^c   Smith, David J ^g   Day, Christopher P ^f   Adams, David H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g Biotie Therapies Corp   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULAR ADHESION PROTEIN 1; AMINE OXIDASE (COPPER CONTAINING); AOC3 PROTEIN, HUMAN; CELL ADHESION MOLECULE; REACTIVE OXYGEN METABOLITE; SEMICARBAZIDE-SENSITIVE AMINE OXIDASE-VASCULAR ADHESION PROTEIN-1, MOUSE;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS; HUMAN; INFLAMMATORY CELL; LEUKOCYTE MIGRATION; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; WOUND CLOSURE; ADULT; ANIMAL; BLOOD; CELL LINE; CELL MOTION; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PATHOLOGY;

ADULT; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; CELL ADHESION MOLECULES; CELL LINE; CELL MOVEMENT; CHRONIC DISEASE; COHORT STUDIES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATITIS; HUMANS; INFLAMMATION; LEUKOCYTES; LIVER CIRRHOSIS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84961291855     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73722     Document Type: Article

References (71)

1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(suppl 1):S5-S10.
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2):S99-S112.
3. Kojima H, et al. Difference and similarity between non-alcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res. 2005;29(12):259S-263S.
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330-344.
5. Day CP. From fat to inflammation. Gastroenterology. 2006;130(1):207-210.
6. Henao-Mejia J, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-185.
7. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med. 2006;6(1):19-25.
8. Lieber CS. Metabolic effects of ethanol and its interaction with other drugs, hepatotoxic agents, vitamins, and carcinogens: a 1988 update. Semin Liver Dis. 1988;8(1):47-68.
9. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123(5):1887-1901.
10. Lalor PF, Shields P, Grant A, Adams DH. Recruitment of lymphocytes to the human liver. Immunol Cell Biol. 2002;80(1):52-64.
11. Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J. 2001;20(15):3893-3901.
12. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol. 2002;169(2):983-992.
13. McNab G, Reeves JL, Salmi M, Hubscher S, Jalkanen S, Adams DH. Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium. Gastroenterology. 1996;110(2):522-528.
14. Yoong KF, McNab G, Hubscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol. 1998;160(8):3978-3988.
15. Bonder CS, et al. Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for alpha-4 integrin and vascular adhesion protein-1. Immunity. 2005;23(2):153-163.
16. Lyles GA. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol. 1996;28(3):259-274.
17. Lalor PF, Sun PJ, Weston CJ, Martin-Santos A, Wakelam MJ, Adams DH. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-κB-dependent increase in lymphocyte adhesion. Hepatology. 2007;45(2):465-474.
18. Jalkanen S, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood. 2007;110(6):1864-1870.
19. Enrique-Tarancon G, et al. Substrates of semicarbazidesensitive amine oxidase co-operate with vanadate to stimulate tyrosine phosphorylation of insulin-receptor-substrate proteins, phosphoinositide 3-kinase activity and GLUT4 translocation in adipose cells. Biochem J. 2000;350(pt 1):171-180.
20. Enrique-Tarancon G, et al. Role of semicarbazidesensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem. 1998;273(14):8025-8032.
21. Marti L, et al. Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide. J Pharmacol Exp Ther. 1998;285(1):342-349.
22. Abella A, et al. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia. 2004;47(3):429-438.
23. Kurkijarvi R, Yegutkin GG, Gunson BK, Jalkanen S, Salmi M, Adams DH. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology. 2000;119(4):1096-1103.
24. Stolen CM, Yegutkin GG, Kurkijarvi R, Bono P, Alitalo K, Jalkanen S. Origins of serum semicarbazidesensitive amine oxidase. Circ Res. 2004;95(1):50-57.
25. Salmi M, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol. 2002;161(6):2255-2262.
26. Kurkijarvi R, Adams DH, Leino R, Mottonen T, Jalkanen S, Salmi M. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol. 1998;161(3):1549-1557.
27. Meszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K. Elevated serum semicarbazidesensitive amine oxidase activity in noninsulindependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism. 1999;48(1):113-117.
28. Karadi I, et al. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta. 2002;323(1):139-146.
29. Boomsma F, et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res. 1997;33(2):387-391.
30. Li HY, et al. Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta. 2009;404(2):149-153.
31. Aalto K, et al. Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations. Arterioscler Thromb Vasc Biol. 2012;32(2):523-532.
32. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321.
33. Lazarus HM, Cruikshank WW, Narasimhan N, Kagan HM, Center DM. Induction of human monocyte motility by lysyl oxidase. Matrix Biol. 1995;14(9):727-731.
34. Lucero HA, et al. Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem. 2008;283(35):24103-24117.
35. Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature. 2009;459(7249):996-999.
36. Ushio-Fukai M. Vascular signaling through G proteincoupled receptors: new concepts. Curr Opin Nephrol Hypertens. 2009;18(2):153-159.
37. Stolen CM, et al. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity. 2005;22(1):105-115.
38. Barry-Hamilton V, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009-1017.
39. Lee WY, Salmi M, Kelly MM, Jalkanen S, Kubes P. Therapeutic advantage of anti-vascular adhesion protein-1 over anti-α4 integrin antibody in concanavalin a-induced hepatitis. Hepatology. 2013;58(4):1413-1423.
40. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117(3):539-548.
41. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martinez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol. 2009;41(5):969-976.
42. Diehl AM. Alcoholic liver disease: natural history. Liver Transpl Surg. 1997;3(3):206-211.
43. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes. 2005;54(5):1314-1323.
44. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol. 2008;173(4):993-1001.
45. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8(1):35-44.
46. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):G987-G995.
47. Weston CJ, Shepherd EL, Adams DH. Cellular localization and trafficking of vascular adhesion protein-1 as revealed by an N-terminal GFP fusion protein. J Neural Transm. 2013;120(6):951-961.
48. Riedl J, et al. Lifeact: a versatile marker to visualize F-actin. Nat Methods. 2008;5(7):605-607.
49. Henao-Mejia J, Elinav E, Strowig T, Flavell RA. Inflammasomes: far beyond inflammation. Nat Immunol. 2012;13(4):321-324.
50. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158-1172.
51. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54(1):133-144.
52. Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis. 2012;16(3):549-565.
53. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810-820.
54. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-172.
55. Klyubin IV, Kirpichnikova KM, Gamaley IA. Hydrogen peroxide-induced chemotaxis of mouse peritoneal neutrophils. Eur J Cell Biol. 1996;70(4):347-351.
56. Lazarus HM, Cruikshank WW, Narasimhan N, Kagan HM, Center DM. Induction of human monocyte motility by lysyl oxidase. Matrix Biol. 1995;14(9):727-731.
57. Lucero HA, et al. Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem. 2008;283(35):24103-24117.
58. Steiniger B, Barth P, Hellinger A. The perifollicular and marginal zones of the human splenic white pulp: do fibroblasts guide lymphocyte immigration? Am J Pathol. 2001;159(2):501-512.
59. Iffiu-Soltesz Z, et al. Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res. 2010;61(4):355-363.
60. Mercader J, Iffiu-Soltesz Z, Bour S, Carpene C. Oral administration of semicarbazide limits weight gain together with inhibition of fat deposition and of primary amine oxidase activity in adipose tissue. J Obes. 2011;2011:475786.
61. Bour S, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 deficiency reduces leukocyte infiltration into adipose tissue and favors fat deposition. Am J Pathol. 2009;174(3):1075-1083.
62. Noonan T, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol. 2013;2(2):172-185.
63. Olivieri A, Tipton K. Inhibition of bovine plasma semicarbazide-sensitive amine oxidase by caffeine. J Biochem Mol Toxicol. 2011;25(1):26-27.
64. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55(2):429-436.
65. Koskinen K, et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood. 2004;103(9):3388-3395.
66. Gokturk C, et al. Overexpression of semicarbazidesensitive amine oxidase in smooth muscle cells leads to an abnormal structure of the aortic elastic laminas. Am J Pathol. 2003;163(5):1921-1928.
67. Cuevas EP, Moreno-Bueno G, Canesin G, Santos V, Portillo F, Cano A. LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. Biol Open. 2014;3(2):129-137.
68. Lugassy J, et al. The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. J Biol Chem. 2012;287(5):3541-3549.
69. Holt AP, Haughton EL, Lalor PF, Filer A, Buckley CD, Adams DH. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology. 2009;136(2):705-714.
70. Hathaway M, Burnett D, Elias E, Adams DH. Secretion of soluble chemotactic factors, including interleukin-6: a mechanism for the recruitment of CD8-positive T lymphocytes to human liver allografts during rejection. Hepatology. 1993;18(3):511-518.
71. Merinen M, Irjala H, Salmi M, Jaakkola I, Hanninen A, Jalkanen S. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol. 2005;166(3):793-800.